This trial will test a new drug, TPN-101, for safety and tolerability in people with ALS or FTD caused by a certain gene mutation.
- Frontotemporal Dementia
- ALS (Amyotrophic Lateral Sclerosis)
1 Primary · 3 Secondary · Reporting Duration: 48 weeks
2 Treatment Groups
TPN-101, 400 mg/day
1 of 2
1 of 2
42 Total Participants · 2 Treatment Groups
Primary Treatment: TPN-101, 400 mg/day · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has this scientific investigation been implemented in numerous locales within the state?
"This study is being conducted in a variety of sites, including the University of California, Irvine (Orange, CA), Massachusetts General Hospital (Boston MA), and Johns Hopkins Outpatient Center (Baltimore MD). There are an additional 12 locations that are accepting participants." - Anonymous Online Contributor
How many trial subjects are engaging in this medical research?
"Correct. Clinicaltrials.gov notes that this trial, which was first published on October 1st 2021, is still actively recruiting participants. The study requires 40 volunteers to participate at 12 different healthcare facilities." - Anonymous Online Contributor
Are any openings available to participate in this experiment?
"The data located on clinicaltrials.gov indicates that this research endeavour is still in recruitment mode, with the initial posting being made October 1st of 2021 and most recent updates occurring November 5th 2022." - Anonymous Online Contributor
Has the FDA signified permission for TPN-101, 400 mg/day?
"Our team has rated TPN-101, 400 mg/day a 2 on the safety scale due to evidence of its security in earlier studies, yet no data indicating that it is an efficacious treatment." - Anonymous Online Contributor